Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.37), $0.02 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.